The Life Sciences Catalyst

Developed through our industry insights and deep relationships across the local and global ecosystem, the Deloitte Life Sciences Catalyst exists to solve the business challenges that keep life sciences leaders and innovators up at night.

Our Business Lounge

Via a virtual and in person events programme, a database of whitepapers and a business surgery programme, the Life Sciences Catalyst facilitates connections between people, businesses, and investors to support companies, regardless of their evolutionary stage.

Working virtually and via our Life Sciences Catalyst Business Lounge, we are ready to help you harness the business opportunities ahead.

In an era where collaboration fosters innovation, we were thrilled to launch of our Life Sciences Catalyst Business Lounge within Deloitte Cambridge in 2024. The lounge offers access to three different zones: the touch-down zone, the collaboration zone, and the executive zone. Membership includes access to all three zones, hot and cold beverages, and use of our state-of-the-art digital collaboration capabilities.

If you have any questions, please email us.

Join the Catalyst community

The Life Sciences Catalyst offers a collaborative platform for growing Biotech and MedTech companies, pharmaceutical companies, technology companies, and prospective investors to come together to tackle the big challenges facing us all. In addition to regular virtual events, the Life Sciences Catalyst will provide access to a range of other benefits such as.

Upcoming events

We opened dedicated space within our 1 Station Square offices to offer an opportunity for our clients and contacts across the industry to meet, share ideas, collaborate and have access to boardroom meeting space and business lab space too.

To find out what we’ve been up to over the last year, and be part of our anniversary gathering, please join us on Wednesday 14 May from 17:30. To register please contact clcampbell@deloitte.co.uk.

please register here.

Previous events

In March 2025 we delved into the strategic choices required to successfully launch in Europe through a go-alone strategy. This event provided valuable insights from our latest thought leadership report, "Biotech European expansion: Unlocking success through a go-alone strategy".

In February 2025 we held a roundtable on Understanding latest trends, incentives and R&D Tax Credits. For further information or a summary of the presentation, please let us know.

Insights

Our latest insight on Biotech European expansion covers the choices to consider for:

  • A successful launch strategy: Including market access sequencing, pricing strategy, and commercial readiness.
  • G&A functions to support a lean launch: Understanding the capabilities needed and forming an outsourcing strategy.
  • Risk mitigation: Structuring a biotech from a tax perspective and building a global organisation.

View our latest insight here

This is the fourth of a series of life sciences and healthcare predictions reports, compromising ten predictions exploring how the world could look in 2030, what it might feel like for different stakeholders in the health ecosystem, the evidence today that informs our views of tomorrow and how AI technologies, specifically GenAI, might help bring the future closer.

View all predictions here

The go-to-market strategies deployed by emerging biotechs to launch their first products into Europe have changed in the last two years. Instead of building their own infrastructure, emerging biotechs are primarily commercialising their products through out-licencing agreements.

View our latest insight here

In recent years, companies operating in the Life Sciences and Healthcare (LSHC) sector are more and more participating in open innovation to overcome various R&D and commercial challenges. The concept of open innovation involves sourcing new technologies, skills, and knowledge from third parties versus adopting more traditional or closed in-house development models. Overall, biopharma assets sourced via open innovation approaches are currently demonstrating a higher probability of later-phase clinical success compared to those from closed model product development. For large pharma companies this is leading to more cost and time effective product development and is shortening the time to market as well as providing wider access to talent, new technologies, broader geographies, and different therapeutic areas. For smaller pharma and biotech companies, open innovation is leading to increased partnerships and out-licensing opportunities, but this is not without challenges. To help smaller LSHC companies better navigate open innovation, Deloitte’s IP Advisory team has identified key areas to address to ensure more successful outcomes including when to seek a partner, identifying the right partner, preparing materials, and deal negotiations skills.

View our latest report here

Webinars

Watch our most recent webinar from November 2024, dedicated to demystifying the complex world of AI regulation and compliance in life sciences.

This session will provide you with an update on the evolving global AI regulatory landscape, with a particular focus on the EU AI Act and its direct implications for your business.

Watch now

In October 2024, we hosted a webinar on digitisation. We were joined by Amazon Web Services, Healthcare and Life Sciences Leader, Himanshu Jain. Scientific data is at the core of every Life Sciences company and organisation. A key challenge many face is getting this valuable data out of the lab and into the decision making processes.

In this webinar we reviewed the common challenges facing labs, how digital solutions can overcome those challenges and discuss how lab digitisation can accelerate your product on its journey from bench to patient.

Watch now

How emerging biotechs are exploring the opportunities of out-licensing

Increasingly, emerging biotech companies enter Europe through partnerships and out-licencing deals due to the lower risk, less cost, and increased speed to market – all of which enable a successful first launch. However, for the right companies, go-alone remains attractive to generate the highest returns.

Following our latest report, hear from Hanno Ronte, Emma Dabbs and Rob Finn discussing the latest trends, choices, and trade-offs to consider.

Watch now

This webinar explored:

  • What are the business model considerations for biotech and pharma tech?
  • How do the different business models generate revenue?
  • What are the measurable risks to assess for valuing a platform based business?
  • What are the key valuation considerations for biotech and pharma tech?

Watch now

Podcast

Our podcast explores the big issues, the emerging trends and the cutting-edge innovations that are shaping the Life Sciences industry. Each month, we will connect with industry experts and leaders from the Biotech, Pharmaceutical and Medical Devices industries to discuss how key trends, explored in our research reports, are charting a new, sustainable future for the Life Sciences Industry.

Click here for all episodes

Register Now